國立高雄大學圖資館 |

Language: English

Back

Current immunotherapeutic strategies...

SpringerLink (Online service)

Current immunotherapeutic strategies in cancer

Record Type:	Electronic resources : Monograph/item
Title/Author:	Current immunotherapeutic strategies in canceredited by Matthias Theobald.
other author:	Theobald, Matthias.
Published:	Cham :Springer International Publishing :2020.
Description:	v, 187 p. :ill., digital ;24 cm.
Contained By:	Springer Nature eBook
Subject:	CancerImmunotherapy.
Online resource:	https://doi.org/10.1007/978-3-030-23765-3
ISBN:	9783030237653$q(electronic bk.)

Current immunotherapeutic strategies in cancer
Current immunotherapeutic strategies in cancer[electronic resource] /edited by Matthias Theobald. - Cham :Springer International Publishing :2020. - v, 187 p. :ill., digital ;24 cm. - Recent results in cancer research,v.2140080-0015 ;. - Recent results in cancer research ;v.192..

Current Development of Monoclonal Antibodies in Cancer Therapy -- Clinical Experience with Bispecific T-Cell Engagers -- Advances and challenges of CAR-modified T cells in clinical trials -- Targeting Cancer with Genetically Engineered TCR-T Cells -- Tailored Vaccines Based on Patient's Cancer Mutanome -- Next-Generation Checkpoint Inhibitors and Immune Agonists.

This book offers a comprehensive review of recent advances in cancer immunotherapy, and explores the value and limitations of the most effective current therapeutic strategies and emerging treatment modalities. It discusses in detail the successes achieved using monoclonal antibodies (mAbs), including developments with regard to conjugated mAbs and also bispecific mAbs as novel treatment options for leukemia and solid tumors. It also examines the advances toward personalized immunotherapy, focusing on the effectiveness of adoptive cell therapy using genetically engineered T cells with tumor-associated antigen-specific T-cell receptors and chimeric antigen receptors, as well as the role of tailored vaccines based on the patient's cancer mutanome. Further, it describes the impressive therapeutic results recently achieved with checkpoint inhibitors, and analyzes novel strategies to modulate the immunosuppressive tumor microenvironment. Written by leading international experts and providing up-to-date information on emerging strategies, such as oncolytic virus-based therapy, epigenetic therapy, and combination therapy, the book appeals to all those with an interest in immunotherapy as it comes of age.

ISBN: 9783030237653$q(electronic bk.)

Standard No.: 10.1007/978-3-030-23765-3doiSubjects--Topical Terms:

201873
Cancer
--Immunotherapy.

LC Class. No.: RC271.I45 / C87 2020

Dewey Class. No.: 616.99406

Current immunotherapeutic strategies in cancer
LDR:02624nmm a2200337 a 4500 001 589694
003 DE-He213
005 20200706034349.0
006 m d
007 cr nn 008maaau
008 210601s2020 sz s 0 eng d
020 $a 9783030237653$q(electronic bk.)
020 $a 9783030237646$q(paper)
024 7 $a 10.1007/978-3-030-23765-3 $2 doi
035 $a 978-3-030-23765-3
040 $a GP $c GP
041 0 $a eng
050 4 $a RC271.I45 $b C87 2020
072 7 $a MJCL $2 bicssc
072 7 $a MED062000 $2 bisacsh
072 7 $a MJCL $2 thema
082 0 4 $a 616.99406 $2 23
090 $a RC271.I45 $b C976 2020
245 0 0 $a Current immunotherapeutic strategies in cancer $h [electronic resource] / $c edited by Matthias Theobald.
260 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2020.
300 $a v, 187 p. : $b ill., digital ; $c 24 cm.
490 1 $a Recent results in cancer research, $x 0080-0015 ; $v v.214
505 0 $a Current Development of Monoclonal Antibodies in Cancer Therapy -- Clinical Experience with Bispecific T-Cell Engagers -- Advances and challenges of CAR-modified T cells in clinical trials -- Targeting Cancer with Genetically Engineered TCR-T Cells -- Tailored Vaccines Based on Patient's Cancer Mutanome -- Next-Generation Checkpoint Inhibitors and Immune Agonists.
520 $a This book offers a comprehensive review of recent advances in cancer immunotherapy, and explores the value and limitations of the most effective current therapeutic strategies and emerging treatment modalities. It discusses in detail the successes achieved using monoclonal antibodies (mAbs), including developments with regard to conjugated mAbs and also bispecific mAbs as novel treatment options for leukemia and solid tumors. It also examines the advances toward personalized immunotherapy, focusing on the effectiveness of adoptive cell therapy using genetically engineered T cells with tumor-associated antigen-specific T-cell receptors and chimeric antigen receptors, as well as the role of tailored vaccines based on the patient's cancer mutanome. Further, it describes the impressive therapeutic results recently achieved with checkpoint inhibitors, and analyzes novel strategies to modulate the immunosuppressive tumor microenvironment. Written by leading international experts and providing up-to-date information on emerging strategies, such as oncolytic virus-based therapy, epigenetic therapy, and combination therapy, the book appeals to all those with an interest in immunotherapy as it comes of age.
650 0 $a Cancer $x Immunotherapy. $3 201873
650 1 4 $a Oncology. $3 195181
650 2 4 $a Immunology. $3 189152
700 1 $a Theobald, Matthias. $3 881673
710 2 $a SpringerLink (Online service) $3 273601
773 0 $t Springer Nature eBook
830 0 $a Recent results in cancer research ; $v v.192. $3 560705
856 4 0 $u https://doi.org/10.1007/978-3-030-23765-3
950 $a Medicine (SpringerNature-11650)